Skip to main content
. 2021 Nov 9;10(1):2000699. doi: 10.1080/2162402X.2021.2000699

Figure 1.

Figure 1.

CS1 expression in MM patient samples and the 5TMM model. (a) CS1 expression was investigated using microarray data of the Heidelberg–Montpellier (HM) cohort. Expression was analyzed in bone marrow stromal cells (BMSC; n = 5), CD14+ (n = 5), CD15+ (n = 5), CD3+ (n = 5), CD34+ (n = 5), naive B-cells (n = 5), CD138+ cells of patients with monoclonal gammopathy of undetermined significance (MGUS; n = 5) and primary MM cells of newly diagnosed patients (n = 206). (b) Using the TT2 cohort, CS1 expression was evaluated in bone marrow plasma cells (BMPC) from healthy donors (n = 22) and at various stages of MM disease including MGUS (n = 44), smoldering MM (SMM) (n = 12) and MM (n = 345). (c) CS1 expression in MM cells derived from newly diagnosed patients (n = 40) and at relapse (n = 39) (MMRF cohort). (d) CS1 expression in NK (idiotype−, NK1.1+), myeloid (idiotype−, CD11b+), T (idiotype−, CD3+) and MM cells (idiotype+) derived from the bone marrow and spleen of the 5T33MM mouse model (n = 3, mean±SD, *p < .05, Mann-Whitney U test). (e) Representative flow cytometry result of CS1 expression in 5T33MM cells derived from spleen and bone marrow. (f) CS1 expression in proliferating and dormant MM cells using the in vivo 5TGM1 myeloma dormancy model. Dormant (5TGM1-GFP+, DiD+) cells and proliferating (5TGM1-GFP+, DiD−) myeloma cells were analyzed for CS1 expression by flow cytometry (n = 3, one representative result is shown)